Brandeis University

[Sidebar#SC145549] Biopharmaceutical companies and other life science start-ups may access $1.28bn in new venture capital available through four different sources, including Eir Venture Partners AB’s

Less than a year after its $80m initial public offering, MeiraGTx Holdings PLC will get $100m up front with potential for significant earn-outs under a multi-part collaboration with Johnson & Johnso

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent M&A activity – licensing and alliances are cover

Advantagene Closes $14.2m Series A Round Immuno-oncology firm Advantagene Inc. raised $14.2m through the sale of its Series A convertible preferred shares to undisclosed investors. National Securi